APPLICATION NUMBER:
22-315

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
**PATENT INFORMATION SUBMITTED WITH THE FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT**

For Each Patent That Claims a Drug Substance (Active Ingredient), Drug Product (Formulation and Composition) and/or Method of Use

The following is provided in accordance with Section 505(b) and (c) of the Federal Food, Drug, and Cosmetic Act.

<table>
<thead>
<tr>
<th>TRADE NAME (OR PROPOSED TRADE NAME)</th>
<th>STRENGTH(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>POSURDAX® (dexamethasone biodegradable intravitreal implant) 0.7 mg</td>
<td>0.7 mg</td>
</tr>
</tbody>
</table>

**ACTIVE INGREDIENT(S)**

- Dexamethasone

**DOSAGE FORM**

- Intravitreal implant

This patent declaration form is required to be submitted to the Food and Drug Administration (FDA) with an NDA application, amendment, or supplement as required by 21 CFR 314.53 at the address provided in 21 CFR 314.53(d)(4).

Within thirty (30) days after approval of an NDA or supplement, or within thirty (30) days of issuance of a new patent, a new patent declaration must be submitted pursuant to 21 CFR 314.53(c)(2)(i) with all of the required information based on the approved NDA or supplement. The information submitted in the declaration form submitted upon or after approval will be the only information relied upon by FDA for listing a patent in the Orange Book.

For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.

**FDA will not list patent information if you file an incomplete patent declaration or the patent declaration indicates the patent is not eligible for listing.**

For each patent submitted for the pending NDA, amendment, or supplement referenced above, you must submit all the information described below. If you are not submitting any patents for this pending NDA, amendment, or supplement, complete above section and sections 5 and 6.

### 1. GENERAL

| a. United States Patent Number | 6,726,918 |
| c. Expiration Date of Patent | 10/20/2020 |
| d. Name of Patent Owner | Allergan, Inc. |
| e. Name of agent or representative who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 505(b)(2) and (b)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States) | Douglas Ingram General Counsel |
| f. Is the patent referenced above a patent that has been submitted previously for the approved NDA or supplement referenced above? | ☑ Yes ☐ No |
| g. If the patent referenced above has been submitted previously for listing, is the expiration date a new expiration date? | ☑ Yes ☐ No |

FORM FDA 3542a (7/07)
For the patent referenced above, provide the following information on the drug substance, drug product and/or method of use that is the subject of the pending NDA, amendment, or supplement.

### 2. Drug Substance (Active Ingredient)

2.1 Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement?

- Yes
- No

2.2 Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement?

- Yes
- No

2.3 If the answer to question 2.2 is "Yes," do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described at 21 CFR 314.83(b).

- Yes
- No

2.4 Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.

2.5 Does the patent claim only a metabolite of the active ingredient in the pending NDA or supplement?

(Complete the information in section 4 below if the patent claims a pending method of using the pending drug product to administer the metabolite.)

- Yes
- No

2.6 Does the patent claim only an intermediate?

- Yes
- No

2.7 If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)

- Yes
- No

### 3. Drug Product (Composition/Formulation)

3.1 Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement?

- Yes
- No

3.2 Does the patent claim only an intermediate?

- Yes
- No

3.3 If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)

- Yes
- No

### 4. Method of Use

Sponsors must submit the information in section 4 for each method of using the pending drug product for which approval is being sought that is claimed by the patent. For each pending method of use claimed by the patent, provide the following information:

4.1 Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement?

- Yes
- No

4.2 Patent Claim Number(s) (as listed in the patent)

1-10, 12-27, 29-31, 36-40

4.2a If the answer to 4.2 is "Yes," identify with specificity the use with reference to the proposed labeling for the drug product.

Use: (Submit indication or method of use information as identified specifically in the approved labeling.)

Method for treating an inflammation-mediated condition of the eye such as macular edema using an intravitreal, biodegradable dexamethasone containing implant.

4.2b Does (Do) the patent claim(s) referenced in 4.2 claim a pending method of use for which approval is being sought in the pending NDA, amendment, or supplement?

- Yes
- No

### 5. No Relevant Patents

For this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (active ingredient), drug product (formulation) or method(s) of use, for which the applicant is seeking approval and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product.
6. Declaration Certification

6.1 The undersigned declares that this is an accurate and complete submission of patent information for the NDA, amendment, or supplement pending under section 505 of the Federal Food, Drug, and Cosmetic Act. This time-sensitive patent information is submitted pursuant to 21 CFR 314.53. I attest that I am familiar with 21 CFR 314.53 and this submission complies with the requirements of the regulation. I verify under penalty of perjury that the foregoing is true and correct.

Warning: A willfully and knowingly false statement is a criminal offense under 18 U.S.C. 1001.

6.2 Authorized Signature of NDA Applicant/Holder or Patent Owner (Attorney, Agent, Representative or other Authorized Official) (Provide Information below)

| □ NDA Applicant/Holder | ☐ NDA Applicant's/Holder's Attorney, Agent (Representative) or other Authorized Official |
| ☐ Patent Owner | ☐ Patent Owner's Attorney, Agent (Representative) or Other Authorized Official |

Name
Elizabeth Bancroft

Address
2525 Dupont Drive
City/State
Irvine, CA

ZIP Code
92612
Telephone Number
(714) 246-4391

FAX Number (if available)
(714) 246-4272
E-Mail Address (if available)
bancroft_elizabeth@allergan.com

The public reporting burden for this collection of information has been estimated to average 20 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
CDER (HFD-407)
5600 Fishers Lane
Rockville, MD 20857

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
Department of Health and Human Services  
Food and Drug Administration  

PATENT INFORMATION SUBMITTED WITH THE  
FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT  

For Each Patent That Claims a Drug Substance  
(Active Ingredient), Drug Product (Formulation and  
Composition) and/or Method of Use  

The following is provided in accordance with Section 505(b) and (c) of the Federal Food, Drug, and Cosmetic Act.

TRADE NAME (OR PROPOSED TRADE NAME)  
POSURDEX® (dexamethasone biodegradable intravitreal implant) 0.7 mg

ACTIVE INGREDIENT(S)  
Dexamethasone

STRENGTH(S)  
0.7 mg

DOSAGE FORM  
Intravitreal implant

This patent declaration form is required to be submitted to the Food and Drug Administration (FDA) with an NDA application, amendment, or supplement as required by 21 CFR 314.53 at the address provided in 21 CFR 314.53(d)(4).

Within thirty (30) days after approval of an NDA or supplement, or within thirty (30) days of issuance of a new patent, a new patent declaration must be submitted pursuant to 21 CFR 314.53(c)(2)(i) with all of the required information based on the approved NDA or supplement. The information submitted in the declaration form submitted upon or after approval will be the only information relied upon by FDA for listing a patent in the Orange Book.

For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.

FDA will not list patent information if you file an incomplete patent declaration or the patent declaration indicates the patent is not eligible for listing.

For each patent submitted for the pending NDA, amendment, or supplement referenced above, you must submit all the information described below. If you are not submitting any patents for this pending NDA, amendment, or supplement, complete above section and sections 5 and 6.

1. GENERAL

a. United States Patent Number  
6,899,717

d. Name of Patent Owner  
Allergan, Inc.

b. Issue Date of Patent  
5/31/2007

Address (of Patent Owner)  
2525 Dupont Drive

City/State  
Irvine, CA

ZIP Code  
92612

Telephone Number  
(714) 246-4391

FAX Number (if available)  
(714) 246-4272

E-Mail Address (if available)  
bancroft_elizabeth@allergan.com

e. Name of agent or representative who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 506(b)(3) and (j)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States)

Douglas Ingram  
General Counsel

Address (of agent or representative named in 1.e.)  
2525 Dupont Drive

City/State  
Irvine, CA

ZIP Code  
92612

Telephone Number  
(714) 246-4535

FAX Number (if available)  
(714) 246-6987

E-Mail Address (if available)  
ingram_doug@allergan.com

f. Is the patent referenced above a patent that has been submitted previously for the approved NDA or supplement referenced above?  
☐ Yes  ☒ No

g. If the patent referenced above has been submitted previously for listing, is the expiration date a new expiration date?  
☐ Yes  ☒ No
For the patent referenced above, provide the following information on the drug substance, drug product and/or method of use that is the subject of the pending NDA, amendment, or supplement.

2. Drug Substance (Active Ingredient)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3 If the answer to question 2.2 is &quot;Yes,&quot; do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described at 21 CFR 314.53(b).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.4 Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5 Does the patent claim only a metabolite of the active ingredient pending in the NDA or supplement? (Complete the information in section 4 below if the patent claims a pending method of using the pending drug product to administer the metabolite.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.6 Does the patent claim only an intermediate?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.7 If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. Drug Product (Composition/Formulation)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.2 Does the patent claim only an intermediate?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3 If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Method of Use

Sponsors must submit the information in section 4 for each method of using the pending drug product for which approval is being sought that is claimed by the patent. For each pending method of use claimed by the patent, provide the following information:

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2 Patent Claim Number(s) (as listed in the patent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2a If the answer to 4.2 is &quot;Yes,&quot; identify with specificity the use with reference to the proposed labeling for the drug product. Use: (Submit indication or method of use information as identified specifically in the approved labeling.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method of delivery on ocular microimplant into a patient's eye to treat diseases of the eye.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. No Relevant Patents

For this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (active ingredient), drug product (formulation or composition) or method(s) of use, for which the applicant is seeking approval and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product.
6. Declaration Certification

6.1 The undersigned declares that this is an accurate and complete submission of patent information for the NDA, amendment, or supplement pending under section 505 of the Federal Food, Drug, and Cosmetic Act. This time-sensitive patent information is submitted pursuant to 21 CFR 314.53. I attest that I am familiar with 21 CFR 314.53 and this submission complies with the requirements of the regulation. I verify under penalty of perjury that the foregoing is true and correct.

Warning: A willfully and knowingly false statement is a criminal offense under 18 U.S.C. 1001.

6.2 Authorized Signature of NDA Applicant/Holder or Patent Owner (Attorney, Agent, Representative or other Authorized Official) (Provide Information below)

<table>
<thead>
<tr>
<th></th>
<th>Date Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Signature]</td>
<td>31 Mar 2008</td>
</tr>
</tbody>
</table>

NOTE: Only an NDA applicant/holder may submit this declaration directly to the FDA. A patent owner who is not the NDA applicant/holder is authorized to sign the declaration but may not submit it directly to FDA. 21 CFR 314.53(c)(4) and (d)(4).

Check applicable box and provide information below.

<table>
<thead>
<tr>
<th>□ NDA Applicant/Holder</th>
<th>□ NDA Applicant/Holder's Attorney, Agent (Representative) or other Authorized Official</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Patent Owner</td>
<td>□ Patent Owner's Attorney, Agent (Representative) or Other Authorized Official</td>
</tr>
</tbody>
</table>

Name
Elizabeth Bancroft

Address
2525 Dupont Drive

City/State
Irvine, CA

ZIP Code
92612

Telephone Number
(714) 246-4391

FAX Number (if available)
(714) 246-4272

E-Mail Address (if available)
bancroft_elizabeth@allergan.com

The public reporting burden for this collection of information has been estimated to average 20 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
CDER (HFD-507)
5600 Fishers Lane
Rockville, MD 20857

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
Department of Health and Human Services  
Food and Drug Administration  

PATENT INFORMATION SUBMITTED WITH THE  
FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT  
For Each Patent That Claims a Drug Substance  
(Active Ingredient), Drug Product (Formulation and Composition) and/or Method of Use  

The following is provided in accordance with Section 505(b) and (e) of the Federal Food, Drug, and Cosmetic Act.

<table>
<thead>
<tr>
<th>TRADE NAME (OR PROPOSED TRADE NAME)</th>
<th>STRONGTH(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>POSURDEX® (dexamethasone biodegradable intravitreal implant) 0.7 mg</td>
<td>0.7 mg</td>
</tr>
</tbody>
</table>

**ACTIVE INGREDIENT(S)**  
Dexamethasone  

**DOSAGE FORM**  
Intravitreal implant

This patent declaration form is required to be submitted to the Food and Drug Administration (FDA) with an NDA application, amendment, or supplement as required by 21 CFR 314.53 at the address provided in 21 CFR 314.53(d)(4).  
Within thirty (30) days after approval of an NDA or supplement, or within thirty (30) days of issuance of a new patent, a new patent declaration must be submitted pursuant to 21 CFR 314.53(c)(2)(ii) with all of the required information based on the approved NDA or supplement. The information submitted in the declaration form submitted upon or after approval will be the only information relied upon by FDA for listing a patent in the Orange Book.

For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.

**FDA will not list patent information if you file an incomplete patent declaration or the patent declaration indicates the patent is not eligible for listing.**

For each patent submitted for the pending NDA, amendment, or supplement referenced above, you must submit all the information described below. If you are not submitting any patents for this pending NDA, amendment, or supplement, complete above section and sections 5 and 6.

### 1. GENERAL

<table>
<thead>
<tr>
<th>a. United States Patent Number</th>
<th>7,033,605</th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Expiration Date of Patent</td>
<td>1/04/2022</td>
</tr>
<tr>
<td>d. Name of Patent Owner</td>
<td>Allergan, Inc.</td>
</tr>
<tr>
<td>e. Address of Patent Owner</td>
<td>2525 Dupont Drive</td>
</tr>
<tr>
<td>City/State</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>ZIP Code</td>
<td>92881</td>
</tr>
<tr>
<td>FAX Number (if available)</td>
<td>714-246-4272</td>
</tr>
<tr>
<td>Telephone Number</td>
<td>714-246-4391</td>
</tr>
<tr>
<td>E-Mail Address (if available)</td>
<td><a href="mailto:banroft_elizabeth@allergan.com">banroft_elizabeth@allergan.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>f. Name of agent or representative who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 505(b)(3) and (b)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.55 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States)</th>
</tr>
</thead>
<tbody>
<tr>
<td>City/State</td>
</tr>
<tr>
<td>ZIP Code</td>
</tr>
<tr>
<td>FAX Number (if available)</td>
</tr>
<tr>
<td>Telephone Number</td>
</tr>
<tr>
<td>E-Mail Address (if available)</td>
</tr>
</tbody>
</table>

| f. Is the patent referenced above a patent that has been submitted previously for the approved NDA or supplement referenced above? | Yes ☑ No  
| ☑ Yes ☑ No |

| g. If the patent referenced above has been submitted previously for listing, is the expiration date a new expiration date? | Yes ☑ No  
| ☑ Yes ☑ No |
For the patent referenced above, provide the following information on the drug substance, drug product and/or method of use that is the subject of the pending NDA, amendment, or supplement.

2. Drug Substance (Active Ingredient)

2.1 Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement?  [ ] Yes  [x] No

2.2 Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement?  [ ] Yes  [x] No

2.3 If the answer to question 2.2 is "Yes," do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described at 21 CFR 314.53(b).  [ ] Yes  [ ] No

2.4 Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.

2.5 Does the patent claim only a metabolite of the active ingredient pending in the NDA or supplement? (Complete the information in section 4 below if the patent claims a pending method of using the pending drug product to administer the metabolite.)  [ ] Yes  [x] No

2.6 Does the patent claim only an intermediate?  [ ] Yes  [x] No

2.7 If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)  [x] Yes  [ ] No

3. Drug Product (Composition/Formulation)

3.1 Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement?  [x] Yes  [ ] No

3.2 Does the patent claim only an intermediate?  [ ] Yes  [x] No

3.3 If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)  [ ] Yes  [x] No

4. Method of Use

Sponsors must submit the information in section 4 for each method of using the pending drug product for which approval is being sought that is claimed by the patent. For each pending method of use claimed by the patent, provide the following information:

4.1 Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement?  [x] Yes  [ ] No

4.2 Patent Claim Number(s) (as listed in the patent)  

| Does (Do) the patent claim(s) referenced in 4.2 claim a pending method of use for which approval is being sought in the pending NDA, amendment, or supplement? |  [x] Yes  [ ] No |

4.2a If the answer to 4.2 is "Yes," identify with specificity the use with reference to the proposed labeling for the drug product. Use: (Submit indication or method of use information as identified specifically in the approved labeling.) Method for treating neovascularization in an eye by implanting in the eye a biodegradable drug delivery system comprising an immunosuppressive agent and a PLGA copolymer.

5. No Relevant Patents

For this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (active ingredient), drug product (formulation or composition) or method(s) of use, for which the applicant is seeking approval and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product.  [ ] Yes
6. Declaration Certification

6.1 The undersigned declares that this is an accurate and complete submission of patent information for the NDA, amendment, or supplement pending under section 505 of the Federal Food, Drug, and Cosmetic Act. This time-sensitive patent information is submitted pursuant to 21 CFR 314.53. I attest that I am familiar with 21 CFR 314.53 and this submission complies with the requirements of the regulation. I verify under penalty of perjury that the foregoing is true and correct.

Warning: A willfully and knowingly false statement is a criminal offense under 18 U.S.C. 1001.

6.2 Authorized Signature of NDA Applicant/Holder or Patent Owner (Attorney, Agent, Representative or other Authorized Official) (Provide Information below)

<table>
<thead>
<tr>
<th>Date Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 Mar 2008</td>
</tr>
</tbody>
</table>

NOTE: Only an NDA applicant/holder may submit this declaration directly to the FDA. A patent owner who is not the NDA applicant/holder is authorized to sign the declaration but may not submit it directly to FDA. 21 CFR 314.53(c)(4) and (d)(4).

Check applicable box and provide information below.

- [x] NDA Applicant/Holder
- [ ] NDA Applicant/holder's Attorney, Agent (Representative) or other Authorized Official
- [ ] Patent Owner
- [ ] Patent Owner's Attorney, Agent (Representative) or Other Authorized Official

Name
Elizabeth Bancroft

Address
2525 Dupont Drive

City/State
Irvine, CA

ZIP Code
92612

Telephone Number
(714) 246-4391

FAX Number (if available)
(714) 246-4272

E-Mail Address (if available)
bancroft_elizabeth@allergan.com

The public reporting burden for this collection of information has been estimated to average 20 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
CDER (HPD-007)
5600 Fishers Lane
Rockville, MD 20857

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
EXCLUSIVITY SUMMARY

NDA # 22-315                  SUPPL # n/a                  HFD # 520/DAIOP

Trade Name  OZURDEX

Generic Name  Dexamethasone intravitreal implant

Applicant Name  Allergan, Inc.

Approval Date, If Known  6/17/09

PART I  IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission.

   a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement?  
      YES ☒  NO ☐

   If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8

   505(b)(1)

   c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety?  (If it required review only of bioavailability or bioequivalence data, answer "no.")  
      YES ☒  NO ☐

   If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

   n/a

   If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

   n/a
d) Did the applicant request exclusivity?  

YES ☒  NO ☐

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

3 years

e) Has pediatric exclusivity been granted for this Active Moiety?  

YES ☐  NO ☒

If the answer to the above question in YES is this approval a result of the studies submitted in response to the Pediatric Written Request?

n/a

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS AT THE END OF THIS DOCUMENT.

2. Is this drug product or indication a DESI upgrade?  

YES ☐  NO ☒

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II  FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES
(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

YES ☒  NO ☐

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).
2. Combination product.

If the product contains more than one active moiety (as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES □  NO □

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA#
NDA#
NDA#

If the answer to Question 1 or 2 under Part II is "NO," go directly to the signature blocks on Page 8. (Caution: The questions in Part II of the summary should only be answered "NO" for original approvals of new molecular entities.) If "YES," go to Part III.

PART III  THREE-YEAR EXCLUSIVITY FOR NDAs AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to Part II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of
summary for that investigation.

YES ☒ NO ☐

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES ☒ NO ☐

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

n/a

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES ☒ NO ☐

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES ☐ NO ☒

If yes, explain:

n/a

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES ☐ NO ☒
If yes, explain:

n/a

(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

Study #206207-008 "A Six-Month, Phase 3, Multicenter, Masked, Randomized Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO) & Study #206207-009 "A Six-Month, Phase 3, Multicenter, Masked, Randomized Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO)

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not revalidate something the agency considers to have been demonstrated in an already approved application.

a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1

YES □ NO ☒

Investigation #2

YES □ NO ☒

If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

n/a
b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

Investigation #1
YES ☐ NO ☒

Investigation #2
YES ☐ NO ☒

If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

n/a

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"): Studies 206207-008 & 206207-009

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

Investigation #1

IND # 58,663 YES ☒ ! NO ☐
! Explain:

Investigation #2

IND # 58,663 YES ☒ ! NO ☒
! Explain:
(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Explain:</td>
<td>Explain:</td>
</tr>
</tbody>
</table>

Investigation #2

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Explain:</td>
<td>Explain:</td>
</tr>
</tbody>
</table>

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
<td>NO</td>
</tr>
</tbody>
</table>

If yes, explain:

n/a

Name of person completing form: Maureen Dillon-Parker & William M. Boyd, M.D.
Title: Chief, Project Management Staff & Clinical Team Leader
Date: 06/02/09

Name of Office/Division Director signing form: Wiley A. Chambers, M.D.
Title: Acting Director

Form OGD-011347; Revised 05/10/2004; formatted 2/15/05
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Wiley Chambers
6/17/2009 01:19:44 PM
1.3.5.3. Exclusivity Request

Allergan, Inc. hereby requests that three years of exclusivity be granted for NDA 22-315, POSURDEX® (dexamethasone biodegradable intravitreal implant), based on compliance with the provisions set forth in 21 CFR 314.108(b)(4).

Allergan, Inc., hereby certifies that to the best of our knowledge, clinical studies 206207-008 and 206207-009 meet the definition of "new clinical investigation" as set forth in 21 CFR 314.108(a), show that the drug product is safe and efficacious for its intended use, and are essential to the approval of this NDA application. Allergan, Inc. is the sponsor of IND 58,663 under which these clinical studies were conducted.

To the best of our knowledge, there are no published studies or publicly available reports of clinical investigations (other than the studies sponsored by the applicant) to support the approval of NDA 22-315 for POSURDEX® (dexamethasone biodegradable intravitreal implant).

Study 206207-008: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO)

Study 206207-009: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO)

Elizabeth Bancroft
Senior Director
Regulatory Affairs

8 December 2008
PEDIATRIC PAGE
(Complete for all filed original applications and efficacy supplements)

NDA/BLA#: 22-315 Supplement Number: 000 NDA Supplement Type (e.g. SE5): ______
Division Name: Division of Anti-Infective and Ophthalmology
PDUSA Goal Date: June 24, 2009 Stamp Date: December 24, 2008
Proprietary Name: OZURDEX
Established/Generic Name: Dexamethasone intravitreal implant
Dosage Form: intravitreal implant
Applicant/Sponsor: Allergan, Inc.

Indication(s) previously approved (please complete this question for supplements and Type 6 NDAs only):
(1) ______
(2) ______
(3) ______
(4) ______

Pediatric use for each pediatric subpopulation must be addressed for each indication covered by current application under review. A Pediatric Page must be completed for each indication.

Number of indications for this pending application(s): 1
(Attach a completed Pediatric Page for each indication in current application.)

Indication: Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retina vein occlusion (CRVO)

Q1: Is this application in response to a PREA PMR? Yes □ Continue
No □ Please proceed to Question 2.
If Yes, NDA/BLA#: ______ Supplement #: ______ PMR #: ______

Does the division agree that this is a complete response to the PMR?
□ Yes. Please proceed to Section D.
□ No. Please proceed to Question 2 and complete the Pediatric Page, as applicable.

Q2: Does this application provide for (If yes, please check all categories that apply and proceed to the next question):
(a) NEW □ active ingredient(s) (includes new combination); □ indication(s); □ dosage form; □ dosing regimen; or □ route of administration?*
(b) □ No. PREA does not apply. Skip to signature block.

*Note for CDER: SE5, SE6, and SE7 submissions may also trigger PREA.

Q3: Does this indication have orphan designation?
□ Yes. PREA does not apply. Skip to signature block.
□ No. Please proceed to the next question.
Q4: Is there a full waiver for all pediatric age groups for this indication (check one)?

☑ Yes: (Complete Section A.)
☐ No: Please check all that apply:
☐ Partial Waiver for selected pediatric subpopulations (Complete Sections B)
☐ Deferred for some or all pediatric subpopulations (Complete Sections C)
☐ Completed for some or all pediatric subpopulations (Complete Sections D)
☐ Appropriately Labeled for some or all pediatric subpopulations (Complete Sections E)
☐ Extrapolation in One or More Pediatric Age Groups (Complete Section F)
(Please note that Section F may be used alone or in addition to Sections C, D, and/or E.)

Section A: Fully Waived Studies (for all pediatric age groups)

Reason(s) for full waiver: (check, and attach a brief justification for the reason(s) selected)

☑ Necessary studies would be impossible or highly impracticable because:
☐ Disease/condition does not exist in children
☑ Too few children with disease/condition to study
☐ Other (e.g., patients geographically dispersed): _______

Studies are impossible or highly impractical because the number of pediatric patients with macular edema due to branch retinal or central retinal vein occlusion is so small.

☐ Product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients AND is not likely to be used in a substantial number of pediatric patients.
☐ Evidence strongly suggests that product would be unsafe in all pediatric subpopulations (Note: if studies are fully waived on this ground, this information must be included in the labeling.)
☐ Evidence strongly suggests that product would be ineffective in all pediatric subpopulations (Note: if studies are fully waived on this ground, this information must be included in the labeling.)
☐ Evidence strongly suggests that product would be ineffective and unsafe in all pediatric subpopulations (Note: if studies are fully waived on this ground, this information must be included in the labeling.)

☐ Justification attached.

If studies are fully waived, then pediatric information is complete for this indication. If there is another indication, please complete another Pediatric Page for each indication. Otherwise, this Pediatric Page is complete and should be signed.

IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (ederpmhs@fda.hhs.gov) OR AT 301-796-0700.
Section B: Partially Waived Studies (for selected pediatric subpopulations)

Check subpopulation(s) and reason for which studies are being partially waived (fill in applicable criteria below):

Note: If Neonate includes premature infants, list minimum and maximum age in "gestational age" (in weeks).

<table>
<thead>
<tr>
<th>Subpopulation</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Not feasible*</th>
<th>Not meaningful therapeutic benefit*</th>
<th>Ineffective or unsafe†</th>
<th>Formulation failed‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>wk. __ mo.</td>
<td>wk. __ mo.</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? ☐ No; ☐ Yes.

Are the indicated age ranges (above) based on Tanner Stage? ☐ No; ☐ Yes.

Reason(s) for partial waiver (check reason corresponding to the category checked above, and attach a brief justification):

# Not feasible:
☐ No necessary studies would be impossible or highly impracticable because:
☐ Disease/condition does not exist in children
☐ Too few children with disease/condition to study
☐ Other (e.g., patients geographically dispersed): 

* Not meaningful therapeutic benefit:
☐ Product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in this/these pediatric subpopulation(s) AND is not likely to be used in a substantial number of pediatric patients in this/these pediatric subpopulation(s).

† Ineffective or unsafe:
☐ Evidence strongly suggests that product would be unsafe in all pediatric subpopulations (Note: if studies are partially waived on this ground, this information must be included in the labeling.)

☐ Evidence strongly suggests that product would be ineffective in all pediatric subpopulations (Note: if studies are partially waived on this ground, this information must be included in the labeling.)

☑ Evidence strongly suggests that product would be ineffective and unsafe in all pediatric subpopulations (Note: if studies are partially waived on this ground, this information must be included in the labeling.)

‡ Formulation failed:
☐ Applicant can demonstrate that reasonable attempts to produce a pediatric formulation necessary for this/these pediatric subpopulation(s) have failed. (Note: A partial waiver on this ground may only cover the pediatric subpopulation(s) requiring that formulation. An applicant seeking a partial waiver on this ground must submit documentation detailing why a pediatric formulation cannot be developed. This submission will be posted on FDA's website if waiver is granted.)

☐ Justification attached.

For those pediatric subpopulations for which studies have not been waived, there must be (1) corresponding study plans that have been deferred (if so, proceed to Sections C and complete the PeRC Pediatric Plan Template); (2) submitted studies that have been completed (if so, proceed to Section D and complete the PeRC Pediatric Assessment form); (3) additional studies in other age groups that are not needed because the drug is appropriately labeled in one or more pediatric subpopulations (if so, proceed to Section E); and/or (4) additional studies in other age groups that are not needed because efficacy is being extrapolated (if so, proceed to Section F). Note that more than one of these options may apply for this indication to cover all of the

IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (cderpms@fda.hhs.gov) OR AT 301-796-0700.
Section C: Deferred Studies (for selected pediatric subpopulations).

Check pediatric subpopulation(s) for which pediatric studies are being deferred (and fill in applicable reason below):

<table>
<thead>
<tr>
<th>Deferrals (for each or all age groups):</th>
<th>Reason for Deferral</th>
<th>Applicant Certification †</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>minimum</td>
<td>maximum</td>
</tr>
<tr>
<td>Neonate</td>
<td>wk. __ mo.</td>
<td>wk. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>yr. __ mo.</td>
<td>yr. __ mo.</td>
</tr>
<tr>
<td>All Pediatric Populations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
</tr>
</tbody>
</table>

Date studies are due (mm/dd/yy): ______

Are the indicated age ranges (above) based on weight (kg)? □ No; □ Yes.
Are the indicated age ranges (above) based on Tanner Stage? □ No; □ Yes.

* Other Reason: ______

† Note: Studies may only be deferred if an applicant submits a certification of grounds for deferring the studies, a description of the planned or ongoing studies, evidence that the studies are being conducted or will be conducted with due diligence and at the earliest possible time, and a timeline for the completion of the studies. If studies are deferred, on an annual basis applicant must submit information detailing the progress made in conducting the studies or, if no progress has been made, evidence and documentation that such studies will be conducted with due diligence and at the earliest possible time. This requirement should be communicated to the applicant in an appropriate manner (e.g., in an approval letter that specifies a required study as a post-marketing commitment.)

If all of the pediatric subpopulations have been covered through partial waivers and deferrals, Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.
**Section D: Completed Studies (for some or all pediatric subpopulations).**

<table>
<thead>
<tr>
<th>Population</th>
<th>minimum</th>
<th>maximum</th>
<th>PeRC Pediatric Assessment form attached?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>__ wk. __ mo.</td>
<td>__ wk. __ mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>All Pediatric Subpopulations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
<td>Yes ☐</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? ☐ No; ☐ Yes.

Are the indicated age ranges (above) based on Tanner Stage? ☐ No; ☐ Yes.

*Note: If there are no further pediatric subpopulations to cover based on partial waivers, deferrals and/or completed studies, Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.*

**Section E: Drug Appropriately Labeled (for some or all pediatric subpopulations):**

Additional pediatric studies are not necessary in the following pediatric subpopulation(s) because product is appropriately labeled for the indication being reviewed:

<table>
<thead>
<tr>
<th>Population</th>
<th>minimum</th>
<th>maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>__ wk. __ mo.</td>
<td>__ wk. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
</tr>
<tr>
<td>All Pediatric Subpopulations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? ☐ No; ☐ Yes.

Are the indicated age ranges (above) based on Tanner Stage? ☐ No; ☐ Yes.

*If all pediatric subpopulations have been covered based on partial waivers, deferrals, completed studies, and/or existing appropriate labeling, this Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.*

**Section F: Extrapolation from Other Adult and/or Pediatric Studies (for deferred and/or completed studies)**

*Note: Pediatric efficacy can be extrapolated from adequate and well-controlled studies in adults and/or other pediatric subpopulations if (and only if) (1) the course of the disease/condition AND (2) the effects of the product are sufficiently similar between the reference population and the pediatric subpopulation for which information will be extrapolated. Extrapolation of efficacy from studies in adults and/or other children usually requires supplementation with other information obtained from the target pediatric subpopulation, such as*

**IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (cederpmhs@fda.hhs.gov) OR AT 301-796-0700.**
Pediatric studies are not necessary in the following pediatric subpopulation(s) because efficacy can be extrapolated from adequate and well-controlled studies in adults and/or other pediatric subpopulations:

<table>
<thead>
<tr>
<th>Population</th>
<th>minimum</th>
<th>maximum</th>
<th>Extrapolated from:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adult Studies?</td>
</tr>
<tr>
<td>Neonate</td>
<td>__ wk. __ mo.</td>
<td>__ wk. __ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>__ yr. __ mo.</td>
<td>__ yr. __ mo.</td>
<td>□</td>
</tr>
<tr>
<td>All Pediatric Subpopulations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
<td>□</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? □ No; □ Yes.

Are the indicated age ranges (above) based on Tanner Stage? □ No; □ Yes.

Note: If extrapolating data from either adult or pediatric studies, a description of the scientific data supporting the extrapolation must be included in any pertinent reviews for the application.

If there are additional indications, please complete the attachment for each one of those indications. Otherwise, this Pediatric Page is complete and should be signed and entered into DFS or DARRTS as appropriate after clearance by PeRC.

This page was completed by:

(See appended electronic signature page)

Regulatory Project Manager

(Revised: 6/2008)

NOTE: If you have no other indications for this application, you may delete the attachments from this document.
Attachment A

(This attachment is to be completed for those applications with multiple indications only.)

Indication #2: _____

Q1: Does this indication have orphan designation?

☐ Yes. PREA does not apply. Skip to signature block.
☐ No. Please proceed to the next question.

Q2: Is there a full waiver for all pediatric age groups for this indication (check one)?

☐ Yes: (Complete Section A.)
☐ No: Please check all that apply:
  ☐ Partial Waiver for selected pediatric subpopulations (Complete Sections B)
  ☐ Deferred for some or all pediatric subpopulations (Complete Sections C)
  ☐ Completed for some or all pediatric subpopulations (Complete Sections D)
  ☐ Appropriately Labeled for some or all pediatric subpopulations (Complete Sections E)
  ☐ Extrapolation in One or More Pediatric Age Groups (Complete Section F)
(Please note that Section F may be used alone or in addition to Sections C, D, and/or E.)

Section A: Fully Waived Studies (for all pediatric age groups)

Reason(s) for full waiver: (check, and attach a brief justification for the reason(s) selected)

☐ Necessary studies would be impossible or highly impracticable because:
  ☐ Disease/condition does not exist in children
  ☐ Too few children with disease/condition to study
  ☐ Other (e.g., patients geographically dispersed): _____

☐ Product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients AND is not likely to be used in a substantial number of pediatric patients.

☐ Evidence strongly suggests that product would be unsafe in all pediatric subpopulations (Note: if studies are fully waived on this ground, this information must be included in the labeling.)

☐ Evidence strongly suggests that product would be ineffective in all pediatric subpopulations (Note: if studies are fully waived on this ground, this information must be included in the labeling.)

☐ Evidence strongly suggests that product would be ineffective and unsafe in all pediatric subpopulations (Note: if studies are fully waived on this ground, this information must be included in the labeling.)

☐ Justification attached.

If studies are fully waived, then pediatric information is complete for this indication. If there is another indication, please complete another Pediatric Page for each indication. Otherwise, this Pediatric Page is complete and should be signed.
### Section B: Partially Waived Studies (for selected pediatric subpopulations)

Check subpopulation(s) and reason for which studies are being partially waived (fill in applicable criteria below):

**Note:** If neonate includes premature infants, list minimum and maximum age in "gestational age" (in weeks).

<table>
<thead>
<tr>
<th></th>
<th>minimum</th>
<th>maximum</th>
<th>Not feasible</th>
<th>Not meaningful therapeutic benefit</th>
<th>Ineffective or unsafe</th>
<th>Formulation failed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td><em>wk.</em> mo.</td>
<td><em>wk.</em> mo.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td><em>yr.</em> mo.</td>
<td><em>yr.</em> mo.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td><em>yr.</em> mo.</td>
<td><em>yr.</em> mo.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td><em>yr.</em> mo.</td>
<td><em>yr.</em> mo.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)?  [ ] No;  [ ] Yes.

Are the indicated age ranges (above) based on Tanner Stage?  [ ] No;  [ ] Yes.

Reason(s) for partial waiver (check reason corresponding to the category checked above, and attach a brief justification):

#  Not feasible:

- [ ] Necessary studies would be impossible or highly impracticable because:
  - Disease/condition does not exist in children
  - Too few children with disease/condition to study
  - Other (e.g., patients geographically dispersed): ___

* Not meaningful therapeutic benefit:

- [ ] Product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in this/these pediatric subpopulation(s) AND is not likely to be used in a substantial number of pediatric patients in this/these pediatric subpopulation(s).

† Ineffective or unsafe:

- [ ] Evidence strongly suggests that product would be unsafe in all pediatric subpopulations (Note: if studies are partially waived on this ground, this information must be included in the labeling.)

- [ ] Evidence strongly suggests that product would be ineffective in all pediatric subpopulations (Note: if studies are partially waived on this ground, this information must be included in the labeling.)

- [ ] Evidence strongly suggests that product would be ineffective and unsafe in all pediatric subpopulations (Note: if studies are partially waived on this ground, this information must be included in the labeling.)

Δ Formulation failed:

- [ ] Applicant can demonstrate that reasonable attempts to produce a pediatric formulation necessary for this/these pediatric subpopulation(s) have failed. (Note: A partial waiver on this ground may only cover the pediatric subpopulation(s) requiring that formulation. An applicant seeking a partial waiver on this ground must submit documentation detailing why a pediatric formulation cannot be developed. This submission will be posted on FDA’s website if waiver is granted.)

[ ] Justification attached.

For those pediatric subpopulations for which studies have not been waived, there must be (1) corresponding study plans that have been deferred (if so, proceed to Section C and complete the PeRC Pediatric Plan Template); (2) submitted studies that have been completed (if so, proceed to Section D and complete the PeRC Pediatric Assessment form); (3) additional studies in other age groups that are not needed because the drug is appropriately labeled in one or more pediatric subpopulations (if so, proceed to Section E); and/or (4) additional studies in other age groups that are not needed because efficacy is being extrapolated (if so,

**IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (cderpmhs@fda.hhs.gov) OR AT 301-796-0700.**
proceed to Section F). Note that more than one of these options may apply for this indication to cover all of the pediatric subpopulations.

Section C: Deferred Studies (for some or all pediatric subpopulations).

Check pediatric subpopulation(s) for which pediatric studies are being deferred (and fill in applicable reason below):

<table>
<thead>
<tr>
<th>Deferrals (for each or all age groups):</th>
<th>Reason for Deferral</th>
<th>Applicant Certification †</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>minimum</td>
<td>maximum</td>
</tr>
<tr>
<td>□ Neonate</td>
<td>_ wk. _ mo.</td>
<td>_ wk. _ mo.</td>
</tr>
<tr>
<td>□ Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
</tr>
<tr>
<td>□ Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
</tr>
<tr>
<td>□ Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
</tr>
<tr>
<td>□ Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
</tr>
<tr>
<td>□ All Pediatric Populations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
</tr>
</tbody>
</table>

Date studies are due (mm/dd/yy): ______

Are the indicated age ranges (above) based on weight (kg)?  ☐ No; ☐ Yes.

Are the indicated age ranges (above) based on Tanner Stage?  ☐ No; ☐ Yes.

* Other Reason: ____

† Note: Studies may only be deferred if an applicant submits a certification of grounds for deferring the studies, a description of the planned or ongoing studies, evidence that the studies are being conducted or will be conducted with due diligence and at the earliest possible time, and a timeline for the completion of the studies. If studies are deferred, on an annual basis applicant must submit information detailing the progress made in conducting the studies or, if no progress has been made, evidence and documentation that such studies will be conducted with due diligence and at the earliest possible time. This requirement should be communicated to the applicant in an appropriate manner (e.g., in an approval letter that specifies a required study as a post-marketing commitment). If all of the pediatric subpopulations have been covered through partial waivers and deferrals, Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.

IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (coderpmhs@fda.hhs.gov) OR AT 301-796-0700.
**Section D: Completed Studies (for some or all pediatric subpopulations).**

<table>
<thead>
<tr>
<th>Population</th>
<th>minimum</th>
<th>maximum</th>
<th>PeRC Pediatric Assessment form attached?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>_wk. _mo.</td>
<td>_wk. _mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>_yr. _mo.</td>
<td>_yr. _mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>_yr. _mo.</td>
<td>_yr. _mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>Other</td>
<td>_yr. _mo.</td>
<td>_yr. _mo.</td>
<td>Yes ☐</td>
</tr>
<tr>
<td>All Pediatric Subpopulations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
<td>Yes ☐</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? ☐ No; ☐ Yes.

Are the indicated age ranges (above) based on Tanner Stage? ☐ No; ☐ Yes.

*Note: If there are no further pediatric subpopulations to cover based on partial waivers, deferrals and/or completed studies, Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.*

**Section E: Drug Appropriately Labeled (for some or all pediatric subpopulations):**

Additional pediatric studies are not necessary in the following pediatric subpopulation(s) because product is appropriately labeled for the indication being reviewed:

<table>
<thead>
<tr>
<th>Population</th>
<th>minimum</th>
<th>maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>_wk. _mo.</td>
<td>_wk. _mo.</td>
</tr>
<tr>
<td>Other</td>
<td>_yr. _mo.</td>
<td>_yr. _mo.</td>
</tr>
<tr>
<td>Other</td>
<td>_yr. _mo.</td>
<td>_yr. _mo.</td>
</tr>
<tr>
<td>Other</td>
<td>_yr. _mo.</td>
<td>_yr. _mo.</td>
</tr>
<tr>
<td>All Pediatric Subpopulations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? ☐ No; ☐ Yes.

Are the indicated age ranges (above) based on Tanner Stage? ☐ No; ☐ Yes.

*If all pediatric subpopulations have been covered based on partial waivers, deferrals, completed studies, and/or existing appropriate labeling, this Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.*
Section F: Extrapolation from Other Adult and/or Pediatric Studies (for deferred and/or completed studies)

Note: Pediatric efficacy can be extrapolated from adequate and well-controlled studies in adults and/or other pediatric subpopulations if (and only if) (1) the course of the disease/condition AND (2) the effects of the product are sufficiently similar between the reference population and the pediatric subpopulation for which information will be extrapolated. Extrapolation of efficacy from studies in adults and/or other children usually requires supplementation with other information obtained from the target pediatric subpopulation, such as pharmacokinetic and safety studies. Under the statute, safety cannot be extrapolated.

Pediatric studies are not necessary in the following pediatric subpopulation(s) because efficacy can be extrapolated from adequate and well-controlled studies in adults and/or other pediatric subpopulations:

<table>
<thead>
<tr>
<th>Population</th>
<th>minimum</th>
<th>maximum</th>
<th>Extrapolated from:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adult Studies?</td>
</tr>
<tr>
<td>Neonate</td>
<td>_ wk. _ mo.</td>
<td>_ wk. _ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
<td>□</td>
</tr>
<tr>
<td>Other</td>
<td>_ yr. _ mo.</td>
<td>_ yr. _ mo.</td>
<td>□</td>
</tr>
<tr>
<td>All Pediatric Subpopulations</td>
<td>0 yr. 0 mo.</td>
<td>16 yr. 11 mo.</td>
<td>□</td>
</tr>
</tbody>
</table>

Are the indicated age ranges (above) based on weight (kg)? □ No; □ Yes.

Are the indicated age ranges (above) based on Tanner Stage? □ No; □ Yes.

Note: If extrapolating data from either adult or pediatric studies, a description of the scientific data supporting the extrapolation must be included in any pertinent reviews for the application.

If there are additional indications, please copy the fields above and complete pediatric information as directed. If there are no other indications, this Pediatric Page is complete and should be entered into DFS or DARRTS as appropriate after clearance by PeRC.

This page was completed by:

(See appended electronic signature page)

Regulatory Project Manager

FOR QUESTIONS ON COMPLETING THIS FORM CONTACT THE PEDIATRIC AND MATERNAL HEALTH STAFF at 301-796-0700

(Revised: 6/2008)

IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (cderpnums@fda.hhs.gov) OR AT 301-796-0700.
Pediatric Research and Equity Act Waivers

NDA 22-315  
Supplement Type:   
Supplement Number:  

Product name and active ingredient/dosage form: OZURDEX (dexamethasone 0.7 mg biodegradable intravitreal implant)

Sponsor: Allergan, Inc.

Indications(s):
(NOTE: If the drug is approved for or Sponsor is seeking approval for more than one indication, address the following for each indication.)

1. Pediatric age group(s) to be waived.

Full waiver for all pediatric groups.

2. Reason(s) for waiving pediatric assessment requirements (choose all that apply and provide justification):

a. Studies are impossible or highly impractical (e.g., the number of pediatric patients is so small or the number is geographically dispersed). If applicable, choose from age-related conditions in Attachment B.

Studies are impossible or highly impractical because the number of pediatric patients with macular edema due to branch retinal vein or central retinal vein occlusion is so small.

b. The product would be ineffective or unsafe in one or more of the pediatric group(s) for which a waiver is being requested. Note: If this is the reason the studies are being waived, this information MUST be included in the pediatric use section of labeling. Please provide the draft language you intend to include in the label. Suggested language includes, “FDA has not required pediatric studies in ages ___ to ___ because (state the safety or effectiveness reason).”

c. The product fails to represent a meaningful therapeutic benefit over existing therapies for pediatric patients and is unlikely to be used in a substantial number of all pediatric age groups or the pediatric age group(s) for which a waiver is being requested.

d. Reasonable attempts to produce a pediatric formulation for one or more of the pediatric age group(s) for which the waiver is being requested have failed. (Provide documentation from Sponsor) Note: Sponsor must provide data to support this claim for review by the Division, and this report submitted by the Sponsor will be publicly posted.
Attachment I

Adult-Related Conditions that do not occur in pediatrics and qualify for a waiver
These conditions qualify for waiver because studies would be impossible or highly impractical

- Age-related macular degeneration
- Alzheimer’s disease
- Amyotrophic lateral sclerosis
- Atherosclerotic cardiovascular disease
- Benign prostatic hypertrophy
- Chronic Obstructive Pulmonary Disease
- Erectile Dysfunction
- Infertility
- Menopausal and perimenopausal disorders
- Organic amnesic syndrome
  (not caused by alcohol or other psychoactive substances)
- Osteoarthritis
- Parkinson’s disease
- Postmenopausal Osteoporosis
- Vascular dementia/ Vascular cognitive disorder/impairment

Cancer:
- Basal cell
- Bladder
- Breast
- Cervical
- Colorectal
- Endometrial
- Gastric
- Hairy cell leukemia
- Lung (small & non-small cell)
- Multiple myeloma
- Oropharynx (squamous cell)
- Ovarian (non-germ cell)
- Pancreatic
- Prostate
- Renal cell
- Uterine
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
------------------------
Wiley Chambers
6/17/2009 01:12:05 PM
1.3.3 Debarment Certification

Allergan, Inc., hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.

[Signature]
Elizabeth Bancroft
Senior Director
Regulatory Affairs

8 December 2008
Date
CERTIFICATION: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

With respect to all covered clinical studies (or specific clinical studies listed below (if appropriate)) submitted in support of this application, I certify to one of the statements below as appropriate. I understand that this certification is made in compliance with 21 CFR part 54 and that for the purposes of this statement, a clinical investigator includes the spouse and each dependent child of the investigator as defined in 21 CFR 54.2(d).

☐ (1) As the sponsor of the submitted studies, I certify that I have not entered into any financial arrangement with the listed clinical investigators (enter names of clinical investigators below or attach list of names to this form) whereby the value of compensation to the investigator could be affected by the outcome of the study as defined in 21 CFR 54.2(a). I also certify that each listed clinical investigator required to disclose to the sponsor whether the investigator had a proprietary interest in this product or a significant equity in the sponsor as defined in 21 CFR 54.2(b) did not disclose any such interests. I further certify that no listed investigator was the recipient of significant payments of other sorts as defined in 21 CFR 54.2(f).

☐ (2) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that based on information obtained from the sponsor or from participating clinical investigators, the listed clinical investigators (attach list of names to this form) did not participate in any financial arrangement with the sponsor of a covered study whereby the value of compensation to the investigator for conducting the study could be affected by the outcome of the study (as defined in 21 CFR 54.2(a)); had no proprietary interest in this product or significant equity interest in the sponsor of the covered study (as defined in 21 CFR 54.2(b)); and was not the recipient of significant payments of other sorts (as defined in 21 CFR 54.2(f)).

☐ (3) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that I have acted with due diligence to obtain from the listed clinical investigators (attach list of names) or from the sponsor the information required under 54.4 and it was not possible to do so. The reason why this information could not be obtained is attached.

NAME: Jeffrey L. Edwards

TITLE: Executive Vice President, Finance and Business Development, Chief Financial Officer

FIRM / ORGANIZATION: Allergan, Inc.

SIGNATURE: [Signature]

DATE: 12-8-08

Paperwork Reduction Act Statement
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 1 hour per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to the address to the right.

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14C-03
Rockville, MD 20857

FORM FDA 3454 (4/06)
DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning [Name of clinical investigator], who participated as a clinical investigator in the submitted study [Allergan Protocol], is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual’s disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

<table>
<thead>
<tr>
<th>NAME</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey L. Edwards</td>
<td>Executive Vice President, Finance and Business Development, Chief Financial Officer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIRM / ORGANIZATION</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan, Inc.</td>
<td>12-8-08</td>
</tr>
</tbody>
</table>

SIGNATURE: [Signature]

Paperwork Reduction Act Statement

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14-72
Rockville, MD 20857

FORM FDA 3455 (4/08)
Page(s) Withheld

☑ Personal Privacy Information (b6)

☐ Trade Secret / Confidential (b4)

☐ Draft Labeling (b4)

☐ Draft Labeling (b5)

☐ Deliberative Process (b5)

Withheld Track Number: Administrative-1
The following information concerning ____________________________________________________________, who participated as a clinical investigator in the submitted study Allergan Protocol ____________________________________________________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual’s disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

<table>
<thead>
<tr>
<th>NAME</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey L. Edwards</td>
<td>Executive Vice President, Finance and Business Development, Chief Financial Officer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIRM / ORGANIZATION</th>
<th>SIGNATURE</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan, Inc.</td>
<td></td>
<td>12-8-08</td>
</tr>
</tbody>
</table>

Paperwork Reduction Act Statement
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14-72
Rockville, MD 20857
Page(s) Withheld

☑ Personal Privacy Information (b6)

☐ Trade Secret / Confidential (b4)

☐ Draft Labeling (b4)

☐ Draft Labeling (b5)

☐ Deliberative Process (b5)

Withheld Track Number: Administrative-2
DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning __________________________, who participated
as a clinical investigator in the submitted study __________________________, is submitted in accordance with 21 CFR part 54. The
named individual has participated in financial arrangements or holds financial interests that are
required to be disclosed as follows:

Please mark the applicable checkboxes.

☐ any financial arrangement entered into between the sponsor of the covered study and the
clinical investigator involved in the conduct of the covered study, whereby the value of the
compensation to the clinical investigator for conducting the study could be influenced by the
outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of
the covered study such as a grant to fund ongoing research, compensation in the form of
equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical
investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in
the sponsor of the covered study.

Details of the individual's disclosable financial arrangements and interests are attached, along with a
description of steps taken to minimize the potential bias of clinical study results by any of the
disclosed arrangements or interests.

NAME
Jeffrey L. Edwards

TITLE
Executive Vice President, Finance and Business
Development, Chief Financial Officer

FIRM / ORGANIZATION
Allergan, Inc.

SIGNATURE

DATE
12-09-05

Paperwork Reduction Act Statement

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB
control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing
instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information.
Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fisher's Lane, Room 14-72
Rockville, MD 20857
<table>
<thead>
<tr>
<th>DEPARTMENT OF HEALTH AND HUMAN SERVICES</th>
<th>PRESCRIPTION DRUG USER FEE COVERSHEET</th>
</tr>
</thead>
</table>

A completed form must be signed and accompany each new drug or biologic product application and each new supplement. See exceptions on the reverse side. If payment is sent by U.S. mail or courier, please include a copy of this completed form with payment. Payment instructions and fee rates can be found on CDER's website: http://www.fda.gov/cder/pdufa/default.htm

<table>
<thead>
<tr>
<th>1. APPLICANT'S NAME AND ADDRESS</th>
<th>4. BLA SUBMISSION TRACKING NUMBER (STN) / NDA NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLERGAN</td>
<td>022315</td>
</tr>
<tr>
<td>Bonnie Salventi</td>
<td></td>
</tr>
<tr>
<td>2025 Dupont Drive</td>
<td></td>
</tr>
<tr>
<td>Irvine CA 92612-1599</td>
<td></td>
</tr>
<tr>
<td>US</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. TELEPHONE NUMBER</th>
<th>5. DOES THIS APPLICATION REQUIRE CLINICAL DATA FOR APPROVAL?</th>
</tr>
</thead>
<tbody>
<tr>
<td>714-246-4791</td>
<td>[x] YES [ ] NO</td>
</tr>
</tbody>
</table>

If your response is "NO" and this is for a supplement, stop here and sign this form. If response is "YES", check the appropriate response below:

[ ] THE REQUIRED CLINICAL DATA ARE CONTAINED IN THE APPLICATION

[ ] THE REQUIRED CLINICAL DATA ARE SUBMITTED BY REFERENCE TO:

<table>
<thead>
<tr>
<th>3. PRODUCT NAME</th>
<th>6. USER FEE I.D. NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posurdex (dexamethasone biodegradable intravitreal implant 0.5 mg)</td>
<td>FD3007376</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCLUSIONS? IF SO, CHECK THE APPLICABLE EXCLUSION.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] A LARGE VOLUME PARENTERAL DRUG PRODUCT APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT BEFORE 9/1/92 (Self Explanatory)</td>
<td>[ ] A 505(b)(2) APPLICATION THAT DOES NOT REQUIRE A FEE</td>
</tr>
</tbody>
</table>

[ ] THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 739(a)(1)(E) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[ ] THE APPLICATION IS SUBMITTED BY A STATE OR FEDERAL GOVERNMENT ENTITY FOR A DRUG THAT IS NOT DISTRIBUTED COMMERCIALY

| 8. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION? [ ] YES [x] NO |
|------------------------------------------------------|----------------------------------|

OMB Statement:
Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services
Food and Drug Administration
CDER, HFD-94
12420 Parklawn Drive, Room 3046
Rockville, MD 20852-1448

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

<table>
<thead>
<tr>
<th>SIGNATURE OF AUTHORIZED COMPANY REPRESENTATIVE</th>
<th>TITLE</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Regulatory Affairs</td>
<td>11/27/206</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. USER FEE PAYMENT AMOUNT FOR THIS APPLICATION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,175,000.00</td>
<td></td>
</tr>
</tbody>
</table>

Form FDA 3397 (03/07)
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications

Memorandum  
***Pre-Decisional Agency Information ***

Date: June 15, 2009

To: Raphael Rodriguez, Project Manager  
Division of Anti-Infective and Ophthalmology Products

From: Beth Carr, Pharm.D., Regulatory Review Officer  
Sheila Ryan, Pharm.D., Group Leader  
Division of Drug Marketing, Advertising, and Communications (DDMAC)

Subject: Tradename™ (dexamethasone intravitreal implant)  
NDA: 22-315

DDMAC has reviewed the proposed package insert (PI) for Tradename™ (dexamethasone intravitreal implant) submitted by Raphael Rodriguez via email (version dated May 28, 2009) and offers the following comments. Please feel free to contact me at (301) 796-3674 with any questions or clarifications.

* Please note that DDMAC did not thoroughly review the sections of this product labeling that pertain to Novadur. Novadur is a drug delivery system and should be reviewed by the Division of Ophthalmic and Ear, Nose, and Throat Devices in CDRH.

Package Insert

HIGHLIGHTS OF PRESCRIBING INFORMATION

CONTRAINDICATIONS

Sponsors can use safety information directly from the HIGHLIGHTS OF PRESCRIBING INFORMATION to satisfy the fair balance of risk information for promotional materials.

- Please consider adding the full statement to the HIGHLIGHTS section regarding ocular or periocular infections.

   "Tradename® is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial
herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases."

- Please consider defining "advanced glaucoma" because this vague terminology may be used to minimize the risk associated with Tradename™ (dexamethasone intravitreal implant). Please also consider this modification in section 4.2 of the Full Prescribing Information.

FULL PRESCRIBING INFORMATION

2 DOSAGE AND ADMINISTRATION

- This section does not describe how often this product can be used. We note that the Adverse Reactions section of the label refers to a possible second follow up injection, but this is not mentioned here. Please include information in this section regarding the frequency of dosage for this product.

5 WARNINGS AND PRECAUTIONS

- In accordance with the January 2006 Guidance for Industry: Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products - Content and Format, please include the following (if available):
  
  o A description of the adverse reaction and outcome (e.g., time to resolution, significant sequelae).

  o An estimate of risk or adverse reaction rate.

  o A discussion of known risk factors for the adverse reaction (e.g., age, gender, race, comorbid conditions, dose, duration of use, coadministered drugs).

  o A discussion of steps to take to reduce the risk of, decrease the likelihood of, shorten the duration of, or minimize the severity of an adverse reaction. These steps could include, for example, necessary evaluation prior to use, titration and other kinds of dose adjustment, monitoring during dose adjustment or prolonged use, avoidance of other drugs or substances, or special care during comorbid events (e.g., dehydration, infection).

  o A discussion of how to treat, or otherwise manage, an adverse reaction that has occurred.
6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

- In accordance with the January 2006 Guidance for Industry: Averse Reactions Section of the Label for Human Prescription Drugs and Biologics – Content and Format, please include the following (if available):
  - Please include an adequate description of the data sources for the adverse event data, as outlined in the guidance. For example, please include the dosage, frequency, and duration of therapy that patients received along with the number of patients who were enrolled in the study and the number of patients who completed treatment.
  - Identify adverse reactions, if any, that resulted in a significant rate of discontinuation or other clinical intervention (e.g., dosage adjustment, need for other therapy to treat an adverse reaction) in clinical trials.

- "Increased IOP with TRADENAME peaked at day 60 and returned to baseline levels by day 180."

Is this statement based off of the averages of those individuals who experienced increased IOP? Did all individuals with increased IOP return to baseline level by day 180? If not, we recommend modifying this statement as it could be used promotionally to state that all patients who experience increased IOP will return to baseline levels by day 180 when this may not be the case.

- "Following a second injection . . . the overall incidence of cataracts was higher after 1 year."

Can this incidence be quantified? If so, please include the incidence in this statement.

8 USE IN SPECIFIC POPULATIONS

8.4 Pediatric Use

- Please consider defining pediatric patients (e.g., < - years of age).
11 DESCRIPTION

- "TRADENAME® is preloaded into a single-use, specially designed DDS® applicator to facilitate injection of the rod-shaped implant directly into the vitreous."

  o Should "DDS® applicator" in this sentence be changed to Novadur?

  o The overall tone of this sentence is promotional in nature. Please consider removing the terms "specially designed," "facilitate," and "directly."

12 CLINICAL PHARMACOLOGY

- "Dexamethasone, a potent corticosteroid, has been shown to. . . ."

Please consider deleting "potent" from this statement, as it is promotional in tone.

14 CLINICAL STUDIES

6.2 Clinical Studies Experience

In accordance with the January 2006 Guidance for Industry: Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format, please include the following:

- It is generally recommended that the discussion of disposition of subjects include the following:
  o The number of subjects enrolled.
  o The number of subjects completing the study.
  o The number of subjects discontinuing the study and the reasons for discontinuation.
  o For a study with a run-in period or other distinct phases, the number of subjects entering each phase and the number of subjects not progressing to the next phase.

- The onset of effect of TRADENAME® occurs within the first two months after implantation in approximately 20-30% of subjects. The duration of effect persists approximately one to three months after onset of this effect.

The first part of this statement seems unnecessary since this information is included in the table in this section. Does the duration of effect still last one to three months after the onset of the effect, if the onset of effect is longer than 2 months? If not, please clarify this statement.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

 /s/  

Beth M Carr  
6/15/2009 09:52:34 AM  
DDMAC PROFESSIONAL REVIEWER
CLINICAL INSPECTION SUMMARY

DATE: 05-27-2009

TO: Raphael Rodriguez, Regulatory Project Manager
Martin Nevitt, M.D., Medical Officer
Division of Anti-Infective and Ophthalmic Products

FROM: Jean Mulinde, M.D.
Good Clinical Practice Branch 2
Division of Scientific Investigations

THROUGH: Tejashri Purohit-Sheth, M.D.
Branch Chief
Good Clinical Practice Branch 2
Division of Scientific Investigations

SUBJECT: Evaluation of Clinical Inspections.

NDA: 22-315

APPLICANT: Allergan

DRUG: POSURDEX® (dexamethasone biodegradable intravitreal implant).

NME: No

THERAPEUTIC CLASSIFICATION: Priority Review

INDICATION: Treatment of macular edema following branch or central retinal vein occlusion.

CONSULTATION REQUEST DATE: 02/11/2009

DIVISION ACTION GOAL DATE: 06/17/2009

PDUFA DATE: 06/24/2009
I. BACKGROUND:

POSURDEX® (dexamethasone biodegradable intravitreal implant) is an intraocular drug delivery system developed for treatment of macular edema of various etiologies and other retinal diseases. The active ingredient, dexamethasone, is a corticosteroid with marked anti-inflammatory activity. Dexamethasone is combined with biodegradable polymers and extruded into a small implant suitable for delivery into the posterior segment of the eye through a specifically designed applicator. POSURDEX® is intended to treat macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). POSURDEX® is the first available treatment for retinal vein occlusion (RVO) that is supported by 2 large, masked, well-controlled clinical studies. A Priority Review has been granted by FDA because this drug is intended to treat a serious, debilitating disease, and because the drug product addresses medical needs unmet by available treatments for macular edema following branch or central retinal vein occlusion. Currently there are no approved pharmacologic therapies for this condition.

To support approval, the Applicant has provided data from two pivotal clinical trials of identical design (Protocol #206207-008, and Protocol #206207-009), which they believe provide sufficient evidence for the safety and efficacy of ophthalmic intravitreal injection of this biodegradable implant containing dexamethasone 0.7 mg in the NOVADUR™ solid polymer drug delivery system.

The protocols inspected include:

1. PROTOCOL NUMBER: 206207-008 “A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion”

This study was a multi-center, masked, randomized, parallel group study (1:1:1 randomization schema for 700 μg DEX PS DDS Applicator System: 350 μg DEX PS DDS Applicator System: Sham DEX PS DDS Applicator System) in adult subjects with macular edema due to BRVO or CRVO. The study was conducted 85 centers in 13 countries. Patients were enrolled in the study from October 22, 2004 through March 31, 2008 (Date of final study report: November 20, 2008).

The primary efficacy variable for the study was the improvement of best-corrected visual acuity (BCVA) as measured by the proportion of subjects achieving a least a 15-letter improvement from baseline in the study eye measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) method.

Secondary efficacy variables included:
   a. Changes in contrast sensitivity (CS) measured by the Pelli-Robson chart in the study eye.
b. Changes in optical coherence tomography (OCT), a laser-based noninvasive, diagnostic system providing high-resolution images of the retina, as read by the central reading center (reading for retinal cystoid spaces and the thickness of the central subfield and/or central point).

c. Assessment of fundus photography (FP) by the Reading Center for quality assessment of OCT images.

d. Fluorescein Angiography (FA) to provide angiographic evidence of leakage improvement at day 180.

Safety endpoints included adverse events, BCVA by ETDRS, intraocular pressure using Goldman applanation tonometer, biomicroscopic examination, lens assessment, indirect ophthalmoscopic examination, retroillumination photography for opacity grading, vital signs, and pregnancy testing.

2. PROTOCOL NUMBER: 206207-009 “A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion”

This study was a multi-center, masked, randomized, parallel group study (1:1:1 randomization schema for 700 μg DEX PS DDS Applicator System: 350 μg DEX PS DDS Applicator System: Sham DEX PS DDS Applicator System) in adult subjects with macular edema due to BRVO or CRVO. The study was conducted 82 centers in 13 countries. Patients were enrolled in the study from November 18, 2004 through March 3, 2008 (Date of final study report: November 17, 2008).

The efficacy and safety endpoints of this study were identical to those in Protocol Number 206207-008.

The clinical investigator (CI) sites that were requested for inspections were those with the highest enrollment numbers at domestic centers for each study. Field inspections of these pivotal studies was considered important as: 1) this is the first Application for use of dexamethasone with this intraocular drug delivery device, and 2) there are no other approved drug products for treatment of macular edema following branch or central retinal vein occlusion (this Application has been granted a priority review based on this basis).

II. RESULTS (by Site):

<table>
<thead>
<tr>
<th>Name of CI, IRB, or Sponsor Location</th>
<th>Protocol # Site # # of Subjects</th>
<th>Inspection Date</th>
<th>Final Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>James H. Miller, MD Southeastern Retina Associates, PC 1124 Weisgarber Road, Suite 207 Knoxville, TN 37909</td>
<td>Protocol #206207-008 Site #4280 13 Subjects</td>
<td>04/08/2009-04/14/2009</td>
<td>Pending (Preliminary classification of NAI)</td>
</tr>
</tbody>
</table>
1. James H. Miller, MD  
Southeastern Retina Associates, PC  
1124 Weisgarber Road, Suite 207  
Knoxville, TN 37909  
Protocol #206207-008, Site #4280  

a. **What was inspected:**  
   This inspection was conducted in accordance with Compliance Program 7348.811 between 04/08/2009-04/14/2009. A total of 23 subjects were screened, 13 subjects were enrolled and 13 completed the study. Records for all 13 enrolled subjects were reviewed to verify, primary efficacy endpoints, adverse event reporting, protocol deviations, that subjects met eligibility criteria and that informed consents were appropriately completed. In addition, drug accountability records, IRB approval and dates, and sponsor monitoring records were reviewed. There were no limitations to the inspection.

b. **General observations/commentary:**  
The inspection of Dr. Miller’s site did not reveal regulatory violations. A Form FDA 483, Inspectional Observations, was not issued.

c. **Assessment of data integrity:**  
Based on communications with the field investigator, data derived from Dr. Miller’s site are considered acceptable.

**Note:** Observations noted above are based on communications with the field investigator, an inspection summary addendum will be generated if conclusions change upon receipt and review of the EIR.

2. Derek Y. Kunimoto, MD  
(replaced Scott R. Sneed MD who was PI from 06/15/2004 to 6/05/2007)  
Retinal Consultants of Arizona, Ltd  
1101 East Missouri Ave  
Phoenix, AZ 85014  
Protocol #206207-009, Site #9341
a. **What was inspected:**

This inspection was conducted in accordance with Compliance Program 7348.811 between 03/25/2009-04/08/2009. A total of 45 subjects were screened, 24 subjects were enrolled and 22 completed the study. Records for all 24 enrolled subjects were reviewed to verify that subjects met eligibility criteria, primary efficacy endpoints, adverse event reporting, protocol deviations, and that informed consents were appropriately completed. Records for 5 subjects were reviewed in depth to verify that source documents supported all data points recorded in CRFs and line listings. In addition, drug accountability records, IRB approval and dates, and sponsor monitoring records were reviewed. There were no limitations to the inspection.

b. **General observations/commentary:**

The inspection of Dr. Kunimoto’s site revealed regulatory violations. A Form FDA 483, Inspectional Observations, was issued to this investigator for:

i. Failure to ensure that the investigation was conducted according to the signed investigator statement and the investigational plan [21 CFR 312.60]. Specifically, for:

   a) Inclusion of one subject that had a history of glaucoma, contrary to protocol eligibility criteria.
   b) Failing to obtain fundus photography on Day 90 of the Initial Treatment phase for one subject (it was obtained approximately 7 weeks late).
   c) Failing to report a vitreous hemorrhage as an adverse event for one subject (this finding was recorded on the examination portion of the case report form).

   ii. Failure to prepare or maintain adequate case histories with respect to data pertinent to the investigation [312.62(b)]. Specifically, for failing to document that Subject #2000 received the protocol required perioperative ophthalmic antibacterial treatment.

c. **Assessment of data integrity:**

Although several regulatory violations were noted, it is unlikely that they significantly affect overall reliability of safety and efficacy data from the site.

IV. **OVERALL ASSESSMENT OF FINDINGS AND RECOMMENDATIONS**

In general, Protocol #206207-008 and Protocol #206207-009 appear to have been conducted adequately and the data in support of the NDA appear reliable.

The final classification of the Clinical Investigator inspection of Dr. Kunimoto is Voluntary Action Indicated (VAI). While regulatory violations occurred at Dr. Kunimoto’s site, the safety and efficacy data from this site are considered reliable.
The preliminary classification of the Clinical Investigator inspection of Dr. Miller is NAI. Upon receipt of the EIR for Dr. Miller an addendum to this clinical inspection summary will be forwarded to the review division should there be a change in the final classification or additional observations of clinical and regulatory significance are discovered after reviewing the EIR.

{See appended electronic signature page}

Jean M. Mulinde, M.D.
Good Clinical Practice Branch II
Division of Scientific Investigations

CONCURRENCE:

{See appended electronic signature page}

Tejashri Purohit-Sheth, M.D.
Branch Chief
Good Clinical Practice Branch II
Division of Scientific Investigations
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jean Mulinde
5/27/2009 09:49:00 AM
MEDICAL OFFICER

Tejashri Purchit-Sheth
5/27/2009 12:29:02 PM
MEDICAL OFFICER
PROPRIETARY NAME REQUEST
- UNACCEPTABLE

Allergan, Inc.
2525 Dupont Drive
Irvine, California 92612

ATTENTION: Elizabeth Bancroft
Senior Director, Regulatory Affairs

Dear Ms. Bancroft:

Please refer to your New Drug Application (NDA) dated December 23, 2008 received December 24, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for dexamethasone intravitreal implant, 0.7 mg.

We also refer to your February 18, 2009 correspondence, received February 19, 2009, requesting review of your proposed proprietary name, Posurdex. We have completed our review of this proposed proprietary name and have concluded that the name Posurdex is unacceptable because the proposed name is orthographically and phonetically similar to the currently marketed product Precedex (dexametomidine hydrochloride injection).

The orthographic similarity of this name pair is attributed to the fact that both names have the same length (i.e., eight letters), begin with the letter ‘P’, and end in ‘-dex’. When the names are scripted these attributes contribute to the orthographic similarity of this name pair. Posurdex and Precedex are phonetically similar as well. Both names begin with the letter ‘P’, contain three syllables, have an ‘s’ sound in the middle of the name, and both names end in ‘-dex’.

Additionally, the established names of these products are orthographically similar which may also contribute to the overall similarity of this name pair and lead to product confusion.

Precedex is indicated for ICU sedation and for procedural sedation, including ophthalmic surgery. Posurdex is an ophthalmic implant with the proposed indication for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion.

Although Posurdex is an implant and Precedex is a solution for injection, both are injectable products and both may be used in ophthalmic procedures based on their approved indications.

It is likely that both Posurdex and Precedex will be ordered on a pharmacy requisition when medications are distributed within a hospital. Since Posurdex and Precedex will each be available as a single strength, the strength may be omitted from the requisition when ordering resulting in practitioners relying solely on the orthographic and phonetic characteristics of the names
Posurdex and Precedex. Thus, the orthographic and phonetic similarities of the proprietary names, the similar established names and context of use increases the risk of confusion between Posurdex and Precedex.

If you have any questions regarding the contents of this letter or any other aspects of the proprietary name review process, call Darrell Jenkins, Safety Regulatory Project Manager in the Office of Surveillance and Epidemiology, at (301) 796-0558. For any other information regarding this application contact the Office of New Drugs (OND), Raphael Rodriguez, Regulatory Project Manager at (301) 796-0798.

Sincerely,

{See appended electronic signature page}

Carol Holquist, RPh
Director
Division of Medication Error Prevention and Analysis
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Carol Holquist
5/20/2009 05:00:19 PM
# ACTION PACKAGE CHECKLIST

<table>
<thead>
<tr>
<th>APPLICATION INFORMATION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA # 22-315</td>
<td>NDA Supplement # n/a</td>
</tr>
<tr>
<td>BLA # n/a</td>
<td>BLA STN #</td>
</tr>
<tr>
<td>If NDA, Efficacy Supplement Type: n/a</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name: OZURDEX</td>
<td></td>
</tr>
<tr>
<td>Established/Proper Name: dexamethasone intravitreal implant</td>
<td></td>
</tr>
<tr>
<td>Dosage Form: intravitreal implant</td>
<td></td>
</tr>
<tr>
<td>Applicant: Allergan, Inc.</td>
<td></td>
</tr>
<tr>
<td>Agent for Applicant (if applicable): n/a</td>
<td></td>
</tr>
<tr>
<td>RPM: Raphael Rodriguez</td>
<td></td>
</tr>
<tr>
<td>Division: Anti-Infective and Ophthalmology Products</td>
<td></td>
</tr>
</tbody>
</table>

505(b)(2) Original NDAs and 505(b)(2) NDA supplements:
Listed drug(s) referred to in 505(b)(2) application (include NDA/ANDA # and drug name(s)):
n/a

Provide a brief explanation of how this product is different from the listed drug:

☐ If no listed drug, check here and explain:

Prior to approval, review and confirm the information previously provided in Appendix B to the Regulatory Filing Review by re-checking the Orange Book for any new patents and pediatric exclusivity. If there are any changes in patents or exclusivity, notify the OND ADRA immediately and complete a new Appendix B of the Regulatory Filing Review.

☐ No changes  ☐ Updated
Date of check:

If pediatric exclusivity has been granted or the pediatric information in the labeling of the listed drug changed, determine whether pediatric information needs to be added to or deleted from the labeling of this drug.

On the day of approval, check the Orange Book again for any new patents or pediatric exclusivity.

- User Fee Goal Date
  Action Goal Date (if different) 06-24-09 06-17-09

- Actions
  - Proposed action
    X AP ☐ TA ☐ AE
    ☐ NA ☐ CR
  - Previous actions (specify type and date for each action taken)
    X None

- Promotional Materials (accelerated approvals only)
  Note: If accelerated approval (21 CFR 314.510/601.41), promotional materials to be used within 120 days after approval must have been submitted (for exceptions, see guidance www.fda.gov/cder/guidance/2197dft.pdf). If not submitted, explain
  ☐ Received

---

1 The Application Information section is (only) a checklist. The Contents of Action Package section (beginning on page 5) lists the documents to be included in the Action Package.
## Application Characteristics

**Review priority:**
- Standard, X Priority

**Chemical classification (new NDAs only):** 3

- X Fast Track
- Rolling Review
- Orphan drug designation

**NDAs:**
- Subpart H: Accelerated approval (21 CFR 314.510)
- Restricted distribution (21 CFR 314.520)
- Subpart I: Approval based on animal studies

**BLAs:**
- Subpart E: Accelerated approval (21 CFR 601.41)
- Restricted distribution (21 CFR 601.42)
- Subpart H: Approval based on animal studies

**Submitted in response to a PMR**

**Submitted in response to a PMC**

**Comments:** ___________

---

### Date reviewed by PeRC (required for approvals only)

<table>
<thead>
<tr>
<th>Date reviewed by PeRC (required for approvals only)</th>
<th>04/08/09</th>
</tr>
</thead>
<tbody>
<tr>
<td>If PeRC review not necessary, explain: ____________</td>
<td></td>
</tr>
</tbody>
</table>

---

### BLAs only: RMS-BLA Product Information Sheet for TBP has been completed and forwarded to ODBS/DRM (approvals only)

- Yes, date ___________

---

### BLAs only: is the product subject to official FDA lot release per 21 CFR 610.2 (approvals only)

- Yes ___________
- No ___________

---

### Public communications (approvals only)

- Office of Executive Programs (OEP) liaison has been notified of action
  - Yes ___________
  - No ___________

- Press Office notified of action (by OEP)
  - Yes ___________

- Indicate what types (if any) of information dissemination are anticipated

- None ___________
  - X HHS Press Release
  - FDA Talk Paper
  - CDER Q&As
  - Other ___________

---

2 All questions in all sections pertain to the pending application, i.e., if the pending application is an NDA or BLA supplement, then the questions should be answered in relation to that supplement, not in relation to the original NDA or BLA. For example, if the application is a pending BLA supplement, then a new RMS-BLA Product Information Sheet for TBP must be completed.
<table>
<thead>
<tr>
<th><strong>Exclusivity</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Is approval of this application blocked by any type of exclusivity?</strong></td>
</tr>
<tr>
<td>X No ☐ Yes</td>
</tr>
<tr>
<td><strong>NDAs and BLAs: Is there existing orphan drug exclusivity for the “same” drug or biologic for the proposed indication(s)? Refer to 21 CFR 316.3(b)(13) for the definition of “same drug” for an orphan drug (i.e., active moiety). This definition is NOT the same as that used for NDA chemical classification.</strong></td>
</tr>
<tr>
<td>X No ☐ Yes</td>
</tr>
<tr>
<td>If yes, NDA/BLA # and date exclusivity expires:</td>
</tr>
<tr>
<td><strong>(b)(2) NDAs only: Is there remaining 5-year exclusivity that would bar effective approval of a 505(b)(2) application? (Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)</strong></td>
</tr>
<tr>
<td>☐ No ☐ Yes</td>
</tr>
<tr>
<td>If yes, NDA # and date exclusivity expires:</td>
</tr>
<tr>
<td><strong>(b)(2) NDAs only: Is there remaining 3-year exclusivity that would bar effective approval of a 505(b)(2) application? (Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)</strong></td>
</tr>
<tr>
<td>☐ No ☐ Yes</td>
</tr>
<tr>
<td>If yes, NDA # and date exclusivity expires:</td>
</tr>
<tr>
<td><strong>(b)(2) NDAs only: Is there remaining 6-month pediatric exclusivity that would bar effective approval of a 505(b)(2) application? (Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.)</strong></td>
</tr>
<tr>
<td>☐ No ☐ Yes</td>
</tr>
<tr>
<td>If yes, NDA # and date exclusivity expires:</td>
</tr>
<tr>
<td><strong>NDAs only: Is this a single enantiomer that falls under the 10-year approval limitation of 505(a)? (Note that, even if the 10-year approval limitation period has not expired, the application may be tentatively approved if it is otherwise ready for approval.)</strong></td>
</tr>
<tr>
<td>X No ☐ Yes</td>
</tr>
<tr>
<td>If yes, NDA # and date 10-year limitation expires:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Patent Information (NDAs only)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patent Information:</strong> Verify that form FDA-3542a was submitted for patents that claim the drug for which approval is sought. If the drug is an old antibiotic, skip the Patent Certification questions.</td>
</tr>
<tr>
<td>X Verified ☐ Not applicable because drug is an old antibiotic.</td>
</tr>
<tr>
<td><strong>Patent Certification [505(b)(2) applications]:</strong> Verify that a certification was submitted for each patent for the listed drug(s) in the Orange Book and identify the type of certification submitted for each patent.</td>
</tr>
<tr>
<td>21 CFR 314.50(h)(1)(i)(A) ☐ Verified</td>
</tr>
<tr>
<td>21 CFR 314.50(h)(1) ☐ (ii) ☐ (iii)</td>
</tr>
<tr>
<td><strong>[505(b)(2) applications] If the application includes a paragraph III certification, it cannot be approved until the date that the patent to which the certification pertains expires (but may be tentatively approved if it is otherwise ready for approval).</strong></td>
</tr>
<tr>
<td>☐ No paragraph III certification Date patent will expire</td>
</tr>
<tr>
<td><strong>[505(b)(2) applications] For each paragraph IV certification, verify that the applicant notified the NDA holder and patent owner(s) of its certification that the patent(s) is invalid, unenforceable, or will not be infringed (review documentation of notification by applicant and documentation of receipt of notice by patent owner and NDA holder). (If the application does not include any paragraph IV certifications, mark “N/A” and skip to the next section below (Summary Reviews)).</strong></td>
</tr>
<tr>
<td>☐ N/A (no paragraph IV certification) ☐ Verified</td>
</tr>
</tbody>
</table>
• [505(b)(2) applications] For each paragraph IV certification, based on the questions below, determine whether a 30-month stay of approval is in effect due to patent infringement litigation.

Answer the following questions for each paragraph IV certification:

(1) Have 45 days passed since the patent owner’s receipt of the applicant’s notice of certification?

(Note: The date that the patent owner received the applicant’s notice of certification can be determined by checking the application. The applicant is required to amend its 505(b)(2) application to include documentation of this date (e.g., copy of return receipt or letter from recipient acknowledging its receipt of the notice) (see 21 CFR 314.52(e))).

If "Yes," skip to question (4) below. If "No," continue with question (2).

(2) Has the patent owner (or NDA holder, if it is an exclusive patent licensee) submitted a written waiver of its right to file a legal action for patent infringement after receiving the applicant’s notice of certification, as provided for by 21 CFR 314.107(f)(3)?

If "Yes," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip the rest of the patent questions.

If "No," continue with question (3).

(3) Has the patent owner, its representative, or the exclusive patent licensee filed a lawsuit for patent infringement against the applicant?

(Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2))).

If "No," the patent owner (or NDA holder, if it is an exclusive patent licensee) has until the expiration of the 45-day period described in question (1) to waive its right to bring a patent infringement action or to bring such an action. After the 45-day period expires, continue with question (4) below.

(4) Did the patent owner (or NDA holder, if it is an exclusive patent licensee) submit a written waiver of its right to file a legal action for patent infringement within the 45-day period described in question (1), as provided for by 21 CFR 314.107(f)(3)?

If "Yes," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).

If "No," continue with question (5).
(5) Did the patent owner, its representative, or the exclusive patent licensee bring suit against the (b)(2) applicant for patent infringement within 45 days of the patent owner's receipt of the applicant's notice of certification?

(Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2)). If no written notice appears in the NDA file, confirm with the applicant whether a lawsuit was commenced within the 45-day period).

If "No," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).

If "Yes," a stay of approval may be in effect. To determine if a 30-month stay is in effect, consult with the OND ADRA and attach a summary of the response.

### CONTENTS OF ACTION PACKAGE

- Copy of this Action Package Checklist
  - Enclosed

- Officer/Employee List
  - List of officers/employees who participated in the decision to approve this application and consented to be identified on this list (approvals only)
    - Included

- Documentation of consent/non-consent by officers/employees
  - Included

- Action Letters
  - Copies of all action letters (including approval letter with final labeling)
    - Action(s) and date(s)
      - Approval 06/17/09

### Labeling

- Package Insert
  - Write submission/communication date at upper right of first page of PI
    - 06/16/09

- Most recent division-proposed labeling (only if generated after latest applicant submission of labeling)
  - 06/16/09

- Most recent submitted by applicant labeling (only if subsequent division labeling does not show applicant version)
  - 06/11/09

- Original applicant-proposed labeling
  - 12/23/08

- Other relevant labeling (e.g., most recent 3 in class, class labeling), if applicable
  - 6/4/09

- Medication Guide/Patient Package Insert/Instructions for Use
  - Write submission/communication date at upper right of first page of each piece
    - Medication Guide
    - Patient Package Insert
    - Instructions for Use
    - None

---

3 Fill in blanks with dates of reviews, letters, etc.
Version: 9/5/08
- Most-recent division-proposed labeling (only if generated after latest applicant submission of labeling)
  - 6/16/09
- Most recent submitted by applicant labeling (only if subsequent division labeling does not show applicant version)
  - 6/11/09
- Original applicant-proposed labeling
  - 12/23/08
- Other relevant labeling (e.g., most recent 3 in class, class labeling), if applicable

Labels (full color carton and immediate-container labels) (write submission/communication date at upper right of first page of each submission)

- Labels enclosed
- Original enclosed
- 6/16/09
- 6/11/09

- Most-recent division proposal for (only if generated after latest applicant submission)
- Most recent applicant-proposed labeling
  - 6/11/09

Labeling reviews (indicate dates of reviews and meetings)

- Proprietary Name
  - Review(s) (indicate date(s))
  - Acceptability/non-acceptability letter(s) (indicate date(s))
  - 05/14/09, 5/28/09, 6/10/09
  - 05/20/09

Administrative / Regulatory Documents

- Administrative Reviews (e.g., RPM Filing Review\(^4\)/Memo of Filing Meeting) (indicate date of each review)
  - 03/03/09
- NDAs only: Exclusivity Summary (signed by Division Director)
  - X Included
- Application Integrity Policy (AIP) Status and Related Documents
  - www.fda.gov/ora/compliance_ref/aip_page.html
- Applicant in on the AIP
  - Yes X No
- This application is on the AIP
  - If yes, Center Director’s Exception for Review memo (indicate date)
  - If yes, OC clearance for approval (indicate date of clearance communication)
  - Yes X No
  - Not an AP action
- Pediatric Page (approvals only, must be reviewed by PERC before finalized)
  - X Included
- Debarment certification (original applications only): verified that qualifying language was not used in certification and that certifications from foreign applicants are cosigned by U.S. agent (include certification)
  - X Verified, statement is acceptable
- Postmarketing Requirement (PMR) Studies
  - Outgoing communications (if located elsewhere in package, state where located)
  - X None
  - Incoming submissions/communications
- Postmarketing Commitment (PMC) Studies
  - Outgoing Agency request for postmarketing commitments (if located elsewhere in package, state where located)
  - X None

\(^4\) Filing reviews for other disciplines should be filed behind the discipline tab.

Version: 9/5/08
Incoming submission documenting commitment

- Outgoing communications (letters except previous action letters, emails, faxes, telecons) Enclosed
- Internal memoranda, telecons, etc. None
- Minutes of Meetings
  - PeRC (indicate date; approvals only) X No mtg
  - Pre-Approval Safety Conference (indicate date; approvals only) ☐ Not applicable 4/08/09
  - Regulatory Briefing (indicate date) ☐ No mtg n/a
  - Pre-NDA/BLA meeting (indicate date) ☐ No mtg 10/30/07; 04/23/08
  - EOP2 meeting (indicate date) ☐ No mtg 09/08/03
  - Other (e.g., EOP2a, CMC pilot programs) None
- Advisory Committee Meeting(s) X No AC meeting
  - Date(s) of Meeting(s)
  - 48-hour alert or minutes, if available

Decisional and Summary Memos

- Office Director Decisional Memo (indicate date for each review) ☐ None
- Division Director Summary Review (indicate date for each review) ☐ None 06/17/09
- Cross-Discipline Team Leader Review (indicate date for each review) ☐ None 06/16/09

Clinical Information

- Clinical Reviews
  - Clinical Team Leader Review(s) (indicate date for each review) n/a see CDTL Review
  - Clinical review(s) (indicate date for each review) 06/15/09
  - Social scientist review(s) (if OTC drug) (indicate date for each review) X None
- Safety update review(s) (indicate location/date if incorporated into another review) In Clinical Review
- Financial Disclosure review(s) or location/date if addressed in another review
  OR
  - If no financial disclosure information was required, review/memo explaining why not In Clinical Review; CDTL Review; Form 3455 included
  - n/a
- Clinical reviews from other clinical areas/divisions/centers (indicate date of each review) ☐ None CDRH 01/21/09
- Controlled Substance Staff review(s) and Scheduling Recommendation (indicate date of each review) X Not needed
- Risk Management
  - Review(s) and recommendations (including those by OSE and CSS) (indicate date of each review and indicate location/date if incorporated into another review) X None
  - REMS Memo (indicate date) none
  - REMS Document and Supporting Statement (indicate date(s) of submission(s)) None requested
- DSI Clinical Inspection Review Summary(ies) (include copies of DSI letters to investigators) Enclosed 05/27/09

Clinical Microbiology X None
- Clinical Microbiology Team Leader Review(s) (indicate date for each review) X None

5 Filing reviews should be filed with the discipline reviews.
Version: 9/5/08
<table>
<thead>
<tr>
<th>Biostatistics</th>
<th>X None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statistical Division Director Review(s) (indicate date for each review)</td>
<td>X None</td>
<td></td>
</tr>
<tr>
<td>Statistical Team Leader Review(s) (indicate date for each review)</td>
<td>X None</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s) (indicate date for each review)</td>
<td>□ None 05/22/09</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Pharmacology</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Pharmacology Division Director Review(s) (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>Clinical Pharmacology Team Leader Review(s) (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>Clinical Pharmacology review(s) (indicate date for each review)</td>
<td>□ None 05/01/09</td>
</tr>
<tr>
<td>DSI Clinical Pharmacology Inspection Review Summary (include copies of DSI letters)</td>
<td>X None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nonclinical</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacology/Toxicology Discipline Reviews</td>
<td></td>
</tr>
<tr>
<td>▪ ADP/T Review(s) (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>▪ Supervisory Review(s) (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>▪ Pharm/tox review(s), including referenced IND reviews (indicate date for each review)</td>
<td>□ None 04/29/09</td>
</tr>
<tr>
<td>▪ Review(s) by other disciplines/divisions/Centers requested by P/T reviewer (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>▪ Statistical review(s) of carcinogenicity studies (indicate date for each review)</td>
<td>X No carc</td>
</tr>
<tr>
<td>▪ ECAC/CAC report/memo of meeting</td>
<td>X None Included in P/T review, page</td>
</tr>
<tr>
<td>▪ DSI Nonclinical Inspection Review Summary (include copies of DSI letters)</td>
<td>X None requested</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CMC/Quality</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMC/Quality Discipline Reviews</td>
<td></td>
</tr>
<tr>
<td>▪ ONDQA/OBP Division Director Review(s) (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>▪ Branch Chief/Team Leader Review(s) (indicate date for each review)</td>
<td>X None</td>
</tr>
<tr>
<td>▪ CMC/product quality review(s) (indicate date for each review)</td>
<td>□ None 05/28/09</td>
</tr>
<tr>
<td>▪ BLAs only: Facility information review(s) (indicate dates)</td>
<td>X None</td>
</tr>
<tr>
<td>Microbiology Reviews</td>
<td>05/04/09 □ Not needed n/a</td>
</tr>
<tr>
<td>▪ NDAs: Microbiology reviews (sterility &amp; pyrogenicity) (indicate date of each review)</td>
<td></td>
</tr>
<tr>
<td>▪ BLAs: Sterility assurance, product quality microbiology (indicate date of each review)</td>
<td></td>
</tr>
<tr>
<td>Reviews by other disciplines/divisions/Centers requested by CMC/quality reviewer (indicate date of each review)</td>
<td>X None</td>
</tr>
<tr>
<td>Environmental Assessment (check one) (original and supplemental applications)</td>
<td></td>
</tr>
<tr>
<td>□ Review &amp; FONSI (indicate date of review)</td>
<td></td>
</tr>
<tr>
<td>□ Review &amp; Environmental Impact Statement (indicate date of each review)</td>
<td></td>
</tr>
</tbody>
</table>

Version: 9/5/08
<table>
<thead>
<tr>
<th>Scenario</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NDAs: Methods Validation</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Facilities Review/Inspection</strong></td>
<td></td>
</tr>
<tr>
<td>- NDAs: Facilities inspections (include EER printout) (<em>date completed must be within 2 years of action date</em>)</td>
<td>Date completed: 05/15/09</td>
</tr>
<tr>
<td>- BLAs:</td>
<td>Date completed:</td>
</tr>
<tr>
<td>- TBP-EER</td>
<td></td>
</tr>
<tr>
<td>- Compliance Status Check (approvals only, both original and all supplemental applications except CBEs) (<em>date completed must be within 60 days prior to AP</em>)</td>
<td></td>
</tr>
</tbody>
</table>
Appendix A to Action Package Checklist

An NDA or NDA supplemental application is likely to be a 505(b)(2) application if:

1. It relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application.

2. Or it relies for approval on the Agency’s previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval.

3. Or it relies on what is "generally known" or "scientifically accepted" about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean any reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations), OTC monograph deviations (see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

1. The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies).

2. And no additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness of the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application.

3. And all other “criteria” are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

1. Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2).

2. Or the applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement.

3. Or the applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your ODE’s ADRA.